These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 38102683

  • 1. Efficacy of recombinant H5 vaccines delivered in ovo or day of age in commercial broilers against the 2015 U.S. H5N2 clade 2.3.4.4c highly pathogenic avian Influenza virus.
    Kapczynski DR, Chrzastek K, Shanmugasundaram R, Zsak A, Segovia K, Sellers H, Suarez DL.
    Virol J; 2023 Dec 15; 20(1):298. PubMed ID: 38102683
    [Abstract] [Full Text] [Related]

  • 2. Protection of commercial turkeys following inactivated or recombinant H5 vaccine application against the 2015U.S. H5N2 clade 2.3.4.4 highly pathogenic avian influenza virus.
    Kapczynski DR, Sylte MJ, Killian ML, Torchetti MK, Chrzastek K, Suarez DL.
    Vet Immunol Immunopathol; 2017 Sep 15; 191():74-79. PubMed ID: 28895870
    [Abstract] [Full Text] [Related]

  • 3. Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus.
    Kapczynski DR, Esaki M, Dorsey KM, Jiang H, Jackwood M, Moraes M, Gardin Y.
    Vaccine; 2015 Feb 25; 33(9):1197-205. PubMed ID: 25613723
    [Abstract] [Full Text] [Related]

  • 4. Examination of the protective efficacy of two avian influenza H5 vaccines against clade 2.3.4.4b H5N8 highly pathogenic avian influenza virus in commercial broilers.
    El-Shall NA, Awad AM, Sedeik ME.
    Res Vet Sci; 2021 Nov 25; 140():125-133. PubMed ID: 34425414
    [Abstract] [Full Text] [Related]

  • 5. Protection of White Leghorn chickens by U.S. emergency H5 vaccination against clade 2.3.4.4 H5N2 high pathogenicity avian influenza virus.
    Bertran K, Balzli C, Lee DH, Suarez DL, Kapczynski DR, Swayne DE.
    Vaccine; 2017 Nov 01; 35(46):6336-6344. PubMed ID: 28554502
    [Abstract] [Full Text] [Related]

  • 6. Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses.
    Kapczynski DR, Pantin-Jackwood MJ, Spackman E, Chrzastek K, Suarez DL, Swayne DE.
    Vaccine; 2017 Nov 01; 35(46):6345-6353. PubMed ID: 28456525
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Protection afforded by avian influenza vaccination programmes consisting of a novel RNA particle and an inactivated avian influenza vaccine against a highly pathogenic avian influenza virus challenge in layer chickens up to 18 weeks post-vaccination.
    Ladman BS, Gelb J, Sauble LA, Murphy MV, Spackman E.
    Avian Pathol; 2019 Aug 01; 48(4):371-381. PubMed ID: 30961360
    [Abstract] [Full Text] [Related]

  • 12. Maternal antibody inhibition of recombinant Newcastle disease virus vectored vaccine in a primary or booster avian influenza vaccination program of broiler chickens.
    Bertran K, Lee DH, Criado MF, Balzli CL, Killmaster LF, Kapczynski DR, Swayne DE.
    Vaccine; 2018 Oct 15; 36(43):6361-6372. PubMed ID: 30241684
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Herpesvirus of turkey-vectored avian influenza vaccine offers cross-protection against antigenically drifted H5Nx highly pathogenic avian influenza virus strains.
    Nassif S, Zaki F, Mourad A, Fouad E, Saad A, Setta A, Felföldi B, Mató T, Kiss I, Palya V.
    Avian Pathol; 2020 Dec 15; 49(6):547-556. PubMed ID: 32615785
    [Abstract] [Full Text] [Related]

  • 15. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
    Kim SM, Kim YI, Park SJ, Kim EH, Kwon HI, Si YJ, Lee IW, Song MS, Choi YK.
    J Virol; 2017 Mar 15; 91(6):. PubMed ID: 28077631
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Development and use of fowlpox vectored vaccines for avian influenza.
    Bublot M, Pritchard N, Swayne DE, Selleck P, Karaca K, Suarez DL, Audonnet JC, Mickle TR.
    Ann N Y Acad Sci; 2006 Oct 15; 1081():193-201. PubMed ID: 17135511
    [Abstract] [Full Text] [Related]

  • 18. Protective efficacy of a prime-boost protocol using H5-DNA plasmid as prime and inactivated H5N2 vaccine as the booster against the Egyptian avian influenza challenge virus.
    Hussein HA, Ahmed BM, Aly SM, El-Deeb AH, El-Sanousi AA, Rohaim MA, Arafa AA, Gadalla MR.
    Acta Virol; 2016 Oct 15; 60(3):307-15. PubMed ID: 27640441
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy of rHVT-AI vector vaccine in broilers with passive immunity against challenge with two antigenically divergent Egyptian clade 2.2.1 HPAI H5N1 strains.
    Rauw F, Palya V, Gardin Y, Tatar-Kis T, Dorsey KM, Lambrecht B, van den Berg T.
    Avian Dis; 2012 Dec 15; 56(4 Suppl):913-22. PubMed ID: 23402112
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.